NeuroSense Therapeutics FY EPS $(0.44) Misses $(0.35) Estimate

NeuroSense Therapeutics (NASDAQ: NRSN) reported a fiscal year earnings per share (EPS) loss of $(0.44), which was 25.71% lower than the analyst consensus estimate of $(0.35). This performance indicates a significant miss in expected earnings.